Sign in →

Test ID VIP Vasoactive Intestinal Polypeptide, Plasma

Test Down Notes

This test is temporarily unavailable. As an alternate, order FVIPL, 75848. For additional details, see test update.


Ordering Guidance


This test should not be requested on patients who have recently received radioactive material.



Specimen Required


Patient Preparation: Fasting (8 hours)

Collection Container/Tube: Lavender top (EDTA)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and aliquot plasma into a plastic vial. Freeze immediately.


Useful For

Detecting vasoactive intestinal polypeptide-producing tumors in patients with chronic diarrheal diseases

Method Name

Radioimmunoassay (RIA)

Reporting Name

Vasoactive Intestinal Polypeptide,P

Specimen Type

Plasma EDTA

Specimen Minimum Volume

0.55 mL

Specimen Stability Information

Specimen Type Temperature Time
Plasma EDTA Frozen 90 days

Clinical Information

Vasoactive intestinal polypeptide (VIP) was originally isolated from porcine small intestine and was recognized by its potent vasodilator activity. This brain/gut hormone has widespread distribution and is present in neuronal cell bodies localized in the central nervous system, digestive, respiratory, and urogenital tracts, and exocrine, thyroid, and adrenal glands. VIP has a wide scope of biological actions. The main effects of VIP include relaxation of smooth muscle (bronchial and vascular dilation), stimulation of gastrointestinal water and electrolyte secretion, and release of pancreatic hormones.

 

VIP-producing tumors (VIPomas) are rare; most (90%) are located in the pancreas. Watery diarrhea, hypokalemia, and achlorhydria are key symptoms.

Reference Values

<75 pg/mL

Cautions

This test should not be requested in patients who have recently received radioisotopes, therapeutically or diagnostically, because of potential assay interference. A recommended time period before collection cannot be made because it will depend on the isotope administered, the dose given, and the clearance rate in the individual patient. Specimens will be screened for radioactivity prior to analysis. Radioactive samples received in the laboratory will be held and assayed after the radioactivity has sufficiently decayed. This will result in a test delay.

Day(s) Performed

Monday, Wednesday

Report Available

4 to 8 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

84586

NY State Approved

Yes